Physician profile
John Loscalzo
NPI 1699758482
$7,887.89
in general payments reported to CMS, 2019-2025
62 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,055 · 2020: $700 · 2021: $1,257 · 2022: $1,462 · 2023: $941 · 2024: $694 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,391 · Education: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.77 |
| Education | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $792.78 | 2019-2025 | |
| Glaxosmithkline, LLC. | $478.72 | 2022-2024 | Ojjaara, Jemperli, Zejula |
| Janssen Biotech, INC. | $407.68 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| E.R. Squibb & Sons, L.L.C. | $377.06 | 2019-2023 | Opdivo |
| Astrazeneca Pharmaceuticals Lp | $363.20 | 2019-2025 | Enhertu |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $332.83 | 2019-2025 | Ultomiris |
| Pfizer INC. | $328.08 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $317.69 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Amgen INC. | $271.55 | 2019-2023 | Lumakras |
| Lilly USA, LLC | $270.03 | 2019-2021 | |
| Daiichi Sankyo INC. | $220.48 | 2019-2024 | Vanflyta, Injectafer |
| Sirtex Medical INC | $204.15 | 2023 | Sir-Spheres Microspheres |
| Astellas Pharma US INC | $167.17 | 2019-2021 | |
| Gilead Sciences, INC. | $164.95 | 2019-2025 | Trodelvy |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Loscalzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.